These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15328183)

  • 1. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
    Martin NE; Brunner TB; Kiel KD; DeLaney TF; Regine WF; Mohiuddin M; Rosato EF; Haller DG; Stevenson JP; Smith D; Pramanik B; Tepper J; Tanaka WK; Morrison B; Deutsch P; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ; Hahn SM
    Clin Cancer Res; 2004 Aug; 10(16):5447-54. PubMed ID: 15328183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
    Hahn SM; Bernhard EJ; Regine W; Mohiuddin M; Haller DG; Stevenson JP; Smith D; Pramanik B; Tepper J; DeLaney TF; Kiel KD; Morrison B; Deutsch P; Muschel RJ; McKenna WG
    Clin Cancer Res; 2002 May; 8(5):1065-72. PubMed ID: 12006520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
    Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
    Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
    Clin Cancer Res; 2005 Jun; 11(11):4151-9. PubMed ID: 15930351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
    Britten CD; Rowinsky EK; Soignet S; Patnaik A; Yao SL; Deutsch P; Lee Y; Lobell RB; Mazina KE; McCreery H; Pezzuli S; Spriggs D
    Clin Cancer Res; 2001 Dec; 7(12):3894-903. PubMed ID: 11751480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
    Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer.
    Robertson JM; Ensminger WD; Walker S; Lawrence TS
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):331-5. PubMed ID: 9069304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.
    Shinchi H; Maemura K; Noma H; Mataki Y; Aikou T; Takao S
    Br J Cancer; 2007 May; 96(9):1353-7. PubMed ID: 17437021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
    Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
    Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
    Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
    Ikeda M; Okusaka T; Ito Y; Ueno H; Morizane C; Furuse J; Ishii H; Kawashima M; Kagami Y; Ikeda H
    Br J Cancer; 2007 Jun; 96(11):1650-5. PubMed ID: 17533388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
    Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
    Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
    Moulder SL; Mahany JJ; Lush R; Rocha-Lima C; Langevin M; Ferrante KJ; Bartkowski LM; Kajiji SM; Noe DA; Paillet S; Sullivan DM
    Clin Cancer Res; 2004 Nov; 10(21):7127-35. PubMed ID: 15534083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.